XHEL
ORIOLA
Market cap211mUSD
Apr 04, Last price
1.02EUR
Name
Oriola Oyj
Chart & Performance
P/E
—
P/S
0.11
EPS
—
Div Yield, %
6.86%
Shrs. gr., 5y
-0.01%
Rev. gr., 5y
-0.49%
Revenues
1.68b
+12.44%
Net income
-20m
L-2.90%
CFO
39m
+303.13%
Dividend
Apr 03, 20250.07 EUR/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Headquartered in Espoo, Finland, Oriola Oyj is a prominent provider of healthcare and wellbeing products and services across Sweden, Finland, and internationally. The company distributes a diverse range of items, including over-the-counter pharmaceuticals, general traded goods, vitamins, dietary supplements, cosmetics, skincare products, sports drinks, and wound care solutions. Beyond product supply, Oriola offers essential services such as logistics, advisory support, sales and marketing, and specialized expert assistance. These services cater to a broad clientele, encompassing pharmaceutical companies, pharmacies (including hospital pharmacies), veterinary practices, and grocery trade shops. Furthermore, the company provides pharmaceutical staffing and medication dose dispensing services for public and private healthcare operators, pharmacies, grocers, and other retailers. As of December 31, 2021, Oriola managed 319 pharmacies in Sweden and maintained an online pharmacy presence. The company officially adopted the name Oriola Oyj in April 2017, having previously operated as Oriola-KD Oyj.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||